Drug Neuroscience

Invega Sustenna

Payments companies reported to CMS as associated with Invega Sustenna. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$12Massociated payments (2023-2025)

21,621clinicians with associated payments

6companies reporting

By year

2023 $3.5M

2024 $4.5M

2025 $4.0M

Payments reported as associated with Invega Sustenna, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Psychiatry $6.0M

Psychiatric/Mental Health (Nurse Practitioner) $3.1M

Physician Assistant $754K

Family $481K

Psychiatric/Mental Health (Registered Nurse) $291K

Nurse Practitioner $276K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Invega Sustenna

These are the largest totals companies reported as associated with Invega Sustenna. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Franklin Cline	Sacramento, CA	Physician Assistant	$321,314.90
Mark Reynolds	Durham, NC	Psychiatry	$320,659.18
Sanford Herman	Jamaica, NY	Psychiatry	$315,954.15
Henry Nasrallah	Cincinnati, OH	Psychiatry	$307,789.41
Mayer Ayyash	Pittsburgh, PA		$295,738.33
George Kruse	Bronx, NY	Psychiatry	$282,183.06
Kimberly Garcia	Allentown, PA	Psychiatric/Mental Health (Registered Nurse)	$281,398.16
Kent Mcdaniel	Glen Allen, VA	Psychiatry	$249,509.83
Rebecca Roma	Pittsburgh, PA	Psychiatry	$239,614.36
Carolyn Rekerdres	Dallas, TX	Psychiatry	$231,593.79

Prescribed Invega Sustenna?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.